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arbara-ann GuinnWe have previously identified the novel Cancer/Testis antigen 
PASD1 by immunoscreening a testis library with pooled acute 
myeloid leukemia (AML) patient sera. To develop a cytotoxic T 
lymphocyte (CTL)-inducing vaccine, we have now investigated the 
carboxy-terminal region, known to contain serological determinants, 
for MHC class I (HLA-A*0201)-binding peptides. Algorithm-
selected natural peptides failed to show detectable HLA-A*0201 
binding in T2 assays. However, anchor-modified analogue peptides 
showed enhanced binding, with decreased off-rates. Analogue 
peptide-loaded antigen-presenting cells (APCs) induced IFN-
production by T cells from normal donors and patients. In addition, 
peptide-specific T cells could be expanded from cancer patients by 
stimulation with the PASD1 analogue peptide Pa14. For clinical 
application, a DNA fusion gene vaccine encoding Pa14 was designed 
and tested in “humanized” mice. Splenocytes from vaccinated mice 
showed in vitro cytotoxicity against tumour cells, either exogenously 
loaded with the corresponding wild-type peptide (Pw8) or expressing 
endogenously processed PASD1 protein. We show for the first time 
that a DNA vaccine encoding an altered PASD1 epitope can induce 
CTLs to target the natural peptide expressed by human tumour cells. 
Keywords: PASD1, immunotherapy, acute myeloid leukemia, 
DNA vaccine, analogue peptide 
Introduction
Cancer/Testis (CT) antigens and, in particular, testis-restricted 
CT antigens, provide attractive targets for cancer 
immunotherapy since their expression in normal tissue is highly 
restricted, being confined to germline tissues such as the testis 
(reviewed in (1, 2)). However, many CT genes characterized in 
solid tumours were found to have infrequent expression in 
myeloid leukemias (3-5).
We used SEREX (reviewed in (6)) with minor modifications 
(7, 8) to immunoscreen a normal donor testis cDNA library 
with the aim of expanding the limited number of CT antigens 
known in acute myeloid leukemia (AML) at that time. We 
isolated PASD1 (9), which had been similarly identified through 
the immunoscreening of a testis library with sera from patients 
with diffuse large B cell lymphoma (DLBCL) (10). PASD1 has 
two known splice variants, PASD1_v1 and the longer PASD1_v2 
(11). Our immunoscreen identified a cDNA which 
encompassed a.a.263-773, a region unique to the longer 
PASD1_v2 variant, as well as the region common to both 
PASD1_v1 and PASD_v2 (a.a.269-639). This cDNA, initially 
designated as GKT-ATA20, was recognized through 
immunoscreening by 35% of presentation AML, 6% of chronic 
myeloid leukemia (CML), and 10% of DLBCL patient sera, but 
not by 18 normal donor sera (9).
Analysis of PASD1 mRNA and protein expression in tumour 
cells has confirmed its potential as a target for cancer immune 
therapy in AML (9), lymphoma (12), and multiple myeloma 
(13). Ait-Tahar et al. (14) demonstrated that cytotoxic T 
lymphocyte (CTL) cell lines from DLBCL patients could kill 
PASD1-positive tumour cells, providing further evidence of the 
immunogenicity of PASD1. Analysis of the common region of 
PASD1 by RT-PCR indicates that PASD1 is one of the most 
frequently expressed CT antigens in presentation AML (33%) 
(9) when compared to other CT antigens known to be expressed 
in AML, such as HAGE (23%) (5), BAGE (27%) (15), and 
RAGE-1 (21%) (16).
We have developed DNA fusion gene vaccines encoding 
tumour antigens linked to the Fragment C (FrC) sequence of 
tetanus toxin (TT) (17). The aim of the design is to activate 
CD4+ T cell help from the anti-TT repertoire to activate 
immunity against weak tumour antigens and to overcome 
potential tolerance (18). For induction of CD8+ T cells, a 
p.DOM-epitope DNA fusion gene vaccine has been designed 
with the FrC sequence reduced to a single domain (DOM), 
thereby decreasing the potential for peptide competition but 
retaining the MHC class II-restricted peptide p30 (19). The 
target epitope-specific sequence is then inserted at the C-
terminus of FrC to aid processing and presentation. In multiple 
models (reviewed in (17)), this p.DOM-epitope design has been 
shown to induce high levels of epitope-specific CD8+ T cells. 
For patients with relapsed prostate cancer, a p.DOM-epitope 
design incorporating a peptide sequence from prostate-specific 
membrane antigen has induced significant levels of epitope-
specific IFN--producing CD8+ T cell responses in an ongoing 
clinical trial (20). Based on these clinical results, we wanted to1 of 10
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Location and modification of potential target peptides within PASD1. (A) Location of wild peptides (a.a. numbers shown) on variant 1 (_v1) and variant 2 (_v2) of 
PASD1. GKT-ATA20 is the region of PASD1 identified by AML patient sera (8). (B) Stabilization of HLA-A2 molecules on the surface of T2 cells using wt (Pw8) or ana-
logue peptides (Pa13 and Pa14). A peptide from CMV was used as a positive control. Faint line: FITC-isotype control; bold line: FITC-HLA-A2-specific antibody. (C) 
Duration of binding of peptides to T2 cells was measured at various time-points after the removal of peptide by FACS analysis of HLA-A2 levels. (D) Purified CD3+ T 
cells were stimulated with autologous DCs loaded with peptides Pa11-Pa16, CMV, FLU, or no peptide. The positive control (Flu or CMV), which gave optimal results, is 
shown. Aliquots of culture supernatant were collected on day 7 and analyzed for IFN- production levels by ELISA.
explore the effectiveness of the p.DOM-epitope design for the 
treatment of myeloid malignancies and to test the capacity of the 
newly described PASD1 CT antigen as a target for CD8+ T cell 
attack. 
Results
Testing of natural and anchor-modified PASD1-derived peptides for 
binding to MHC class I molecules
We focused our studies on the region of PASD1 (a.a. 269-773) 
which was recognized by AML patient sera and previously 
denoted as GKT-ATA20 (9) (Figure 1A). We identified seven 
peptides (Pw4-10) with HLA-A*0201 binding motifs that were 
specific to PASD1 and no other known eukaryotic proteins (as 
determined by BLAST searches) (Table 1). However, the 
SYFPEITHI binding scores were low and none of the wild-type 
(wt) peptides showed detectable binding to HLA-A2 molecules 
in T2 assays. Substitution of a single anchor residue within the 
Pw4, Pw8, and Pw9 wt peptides was found to improve some of 
the predicted MHC class I binding scores, and these peptide 
analogues (Pa11-Pa16) were investigated further (Table 1). All 
of the Pa11-Pa16 peptide analogues showed detectable binding 
to HLA-A2 molecules in T2 assays and modification of the 
peptides led to decreased off rates. Of note, the Pa13 and Pa14 
peptide analogues, derived from the Pw8 peptide, showed the 
greatest stabilization of HLA-A2 molecules (Figure 1, B and C). 
Modified PASD1 peptides can stimulate T cells from normal donors
In order to assess whether there is a repertoire of peptide-
specific CD8+ T cells capable of being mobilized against target 
cells, the ability of T cells from normal donors to recognize wt or 
modified peptides was investigated. The capacity of the wt 
(Pw4-10) and analogue (Pa11-Pa16) peptides to induce IFN-
secretion from six normal HLA-A2-positive donor T cell 
samples were examined. Unlike the wt peptides, which failed to 
induce significant responses (data not shown), each peptide an-
Table 1 
Mapping of the PASD1 epitopes, wild-type Pw4-Pw10, and ana-
logues Pa11-Pa16.2 of 10 www.cancerimmunity.org
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Detection of Pa14-specific T cells from healthy donors and patients. Pa14-specific T cells were detected in peptide-stimulated primary cell cultures from normal 
donors or from patients. CD3+ cells from (A) normal donor I and (B) AML patient I after 4 (normal donor) or 2 stimulations (AML patient). CD3+ cells from a colon 
cancer patient after (C) 3 weeks of stimulation and (D) 4 weeks of stimulation in culture. Pentamer-PE (FL2-H)-staining CD8+ T cells are shown as a percentage of the 
CD8+ T cells; the amount of IFN- secretion shown as (E) pg/106 CD8+ T cells from the Pa14-specific T cells from AML patients compared to the response to FLU pep-
tide and (F) pg/105 CD8+ T cells from the Pa14-specific T cells from the colon patient compared to the response to CMV peptide, both measured on day 10 of culture by 
ELISA.
alogue stimulated notable levels of IFN- secretion from at least 
one of the six normal donor T cells, with Pa13 and Pa14 
inducing significant levels of IFN- secretion in three of six 
normal donors (normal donors I, II, and VI) (Figure 1D).
Peptide-specific CD8+ cells were detectable in cultures from normal 
donors and patients after stimulation in vitro with Pa14
Due to the relatively frequent and enhanced ability of Pa14 to 
induce IFN- from normal donors, we selected this analogue for 
further investigation. In two of the three normal donors which 
had shown IFN- responses against Pa14 (normal donors I and 
II), it was possible to expand a detectable population of Pa14-
specific pentamer-binding T cells after four rounds of 
stimulation (Figure 2A).
The capacity of T cells from patients with AML to recognize 
the selected Pa14 peptide was then investigated. In two of the 
AML patient cultures (Patients I and II) of the three who 
expressed PASD1 transcripts, small expansions of pentamer-
binding specific T cells were observed after two stimulations 
with Pa14 (Figure 2A), after which time the T cells died. Pa14-
responsive T cells from these AML patients were shown to 
produce IFN- in response to Pa14 10 days and 14 days into the 
culture period as measured by ELISA (Figure 2B). In contrast, T 
cells from a HLA-A2-positive colon cancer patient showed a 
significant increase in Pa14-specific T cells after 3 weeks 
(Figure 2C) and 4 weeks (Figure 2D). IFN- analysis of the 
culture media indicated that significant IFN- was produced by 
T cells responding to Pa14 but not irrelevant, Pa15 or CMV 
epitopes (Figure 2, E and F).
DNA vaccination with the PASD1-derived analogue peptide (Pa14) 
sequence induces responses against Pa14 which cross-reacts with the 
wt (Pw8) peptide
The previous experiments suggested that there was an 
available T cell repertoire against the Pa14 peptide and we 
therefore developed a vaccine strategy for patients. A p.DOM-
epitope vaccine was prepared containing the Pw8 wt or Pa14 
analogue peptide (Figure 3A). HHD mice were injected with 
either the p.DOM-Pw8 or p.DOM-Pa14 DNA vaccine and T cell 
responses examined at day 14. Using an ELISPOT assay for IFN-
 production, T cell responses against the vaccine-encoded 
peptide or an irrelevant control peptide were measured. We 
found that in all mice tested, the p.DOM-Pw8 vaccine failed to 
induce detectable CD8+ T cell responses against Pw8, as 
measured by IFN- production in ELISPOT assays (Figure 3B). 
In contrast, vaccination with p.DOM-Pa14 alone produced 
strong T cell responses against Pa14 as measured in vitro by 
IFN- production in ELISPOT assays (Figure 3B).
Crucially, T cells from mice primed with p.DOM-Pa14 could 
also respond to the wt Pw8 peptide in vitro (Figure 3C). All 
vaccinated mice also generated a p30 response confirming the 
operational integrity of the vaccines. Control mice injected with 
p.DOM vaccine alone failed to induce a response to either Pa14 
or Pw8 peptide, as expected (data not shown).www.cancerimmunity.org 3 of 10
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Design and operation of p.DOM-epitope vaccines. Vaccination of HHD mice with p.DOM-Pa14 induced T cell responses against Pa14 which recognized the wt Pw8 
peptide. (A) p.DOM-epitope vaccine contains the first domain of tetanus toxin attached by a natural linker to the Pw8 or Pa14 epitopes. (B) In priming experiments, 
mice were immunized with either p.DOM-Pw8 (n = 5) or p.DOM-Pa14 (n = 6). On day 14, ELISPOT assays for IFN- were performed using individual mice. Responses 
shown are to the immunizing peptide and demonstrate that, unlike p.DOM-Pa14, priming with p.DOM-Pw8 is insufficient to generate an IFN- response, although a 
response to the p30 peptide is induced. Lymphocytes from immunized mice were incubated with a range of peptide concentrations (10-6 – 10-10 uM). (C) In priming 
experiments, mice were immunized with p.DOM-Pa14 (n = 6) and, 14 days later, ELISPOT assays for IFN- were performed. Responses against both Pa14 and the wt 
Pw8 peptide were detected. Group means are represented by a horizontal bar and data is representative of at least three independent experiments. (D) Splenocytes from 
mice immunized with p.DOM-Pa14 were stimulated for one week in vitro before assessing cytotoxicity by 51Cr-release assay. Cytotoxicity was assessed against mouse 
RMA tumour cells stably transduced with the chimeric humanized MHC class I molecule HHD. RMA-HHD cells were pulsed with either Pw8 or Pa14 peptide or no 
peptide at all. Data is representative of at least three independent experiments.
T cells expanded with Pa14 peptide were also able to lyse 
RMA-HHD target cells loaded with either the Pa14 analogue or 
wt peptide (Pw8) at comparable levels (Figure 3D). Lysis was not 
observed against target cells pulsed with an irrelevant peptide 
(data not shown).
It appears that the wt peptide Pw8 was incapable of inducing 
an effective CD8+ T cell response under these conditions. 
However, the vaccine encoding the analogue peptide (p.DOM-
Pa14) induced a high level response against the analogue 
peptide (Figure 3B) which cross-reacted with the wt Pw8 
peptide (Figure 3, C and D).
CTL lines induced by vaccination with p.DOM-Pa14 lysed human 
target cells naturally expressing full length PASD1
Immunolabeling showed that a proportion of K562 cells 
expressed PASD1 (Figure 4A), while SW480 cells has been 
previously shown to express PASD1 (9). K562 is MHC class I-
negative, while SW480 expresses HLA-A2 (Figure 4B). 
Following transduction of the K562 cell line with the HHD-
containing retrovirus, the ability of Pa14-specific CTL lines exp-
anded from vaccinated mice to kill the human cell lines were 
investigated. Mice were primed and boosted with p.DOM-Pa14, 
and splenocytes from each mouse were stimulated ex vivo with 
Pa14.
We showed that killing of the HLA-A2+ SW480 was far more 
effective than that of the HLA-A2- K562 cells (Figure 4C). 
SW480 (Figure 4D) cell lysis was reproducibly inhibited by the 
HLA-A2 binding antibody W6/32 suggesting that lysis was 
MHC class I-mediated. We showed in multiple experiments that 
CTL lines could kill Pw8-loaded K562-HHD cells, albeit at high 
levels which do not indicate whether physiological levels would 
be recognized (Figure 4, E and F), but do show the capacity of 
these lines to kill cells presenting wt peptide.
In addition, CTL lines showed reproducible but low levels of 
killing of K562-HHD cells in the absence of exogenous peptide 
loading (Figure 4, E and F) when compared to parental (K562) 
and retroviral vector containing control cells (K562-RV), 
reflecting the heterogeneous expression of PASD1 in K562 cells. 
This suggests that the native Pw8 peptide was processed and 
presented from endogenously produced PASD1_v2.
Discussion
We have developed a p.DOM-epitope vaccine encoding an 
analogue from the novel AML-associated CT antigen PASD1. 
When human T cells showed poor responses against the wt 
PASD1 peptides, we modified single anchor residues to improve 
MHC class I binding and extended the time period available for 
T cells to recognize the presented peptide. Success of this 
strategy is dependent on the TCR binding portion of the peptide 
not being altered significantly by anchor residue substitution 
(21). Similar modifications have led to peptide analogues which 
are effective at inducing immune responses against a range of 
tumour types including leukemias and solid tumours (22-27). 
Despite inherent problems demonstrating the ability of 
modified peptides to recognize and kill tumour cells, some 
heteroclitic epitopes have now shown promise in phase I clinical 
trials (28-30). We found that all of the anchor residue substitu-4 of 10 www.cancerimmunity.org
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Lysis of HHD-transduced or HLA-A2-positive human cancer cells by CTL lines from p.DOM-Pa14 immunized mice. Following the vaccination of HHD mice with 
p.DOM-Pa14, splenocytes were stimulated in vitro with 1 μM of Pa14 peptide on a weekly basis. (A) Immunolabeling showed PASD1b expression in a proportion of 
K562 and in H1299 cells but not 697 cells. (B) K562 cells were transduced with either the MSCV retroviral vector alone (K562-RV) or the MSCV-HHD retrovirus (K562-
HHD). Single black lines indicate the expression detected by the HLA-A2 antibody; grey line indicates isotype control; and light grey, cells alone. (C) Lysis of K562 and 
SW480 in the absence of retroviral transduction demonstrated that CTLs could kill the SW480 cell line, which is HLA-A2-positive, and PASD1 expressing with high effi-
ciency at an E:T ratio of 120:1. (D) Lysis of SW480 cells were reproducibly inhibited by the HLA-A2 binding antibody W6/32, suggesting that lysis was MHC class I-
mediated. (E and F) Independent experiments showed that CTL lines could kill Pw8-loaded K562-HHD cells, albeit at high E:T ratios. In addition, CTL lines could lyse 
endogenously processed Pw8 peptide from PASD1 within the K562-HHD cells. Data is representative of a number of independent experiments.
tions increased the stabilization of the derivative Pa11-Pa16 
epitopes which then bound effectively to HLA-A2. In addition, 
the peptide analogues showed an increased efficacy in inducing 
IFN- secretion from normal and patient T cells and 
demonstrated that there is a potential Pa14 repertoire available 
in humans. We focused on one of the most effective peptides 
(Pa14).
We were unable to expand Pa14-specific T cells from two of 
the four HLA-A2-positive AML patient samples examined. Of 
these two, one was PASD1-negative (Patient III) and the other 
had PASD1-positive AML cells, but had received a single course 
of chemotherapy treatment. In two AML patients (Patients I and 
II), a small but clinically relevant number of Pa14-specific T cells 
were expanded after two rounds of Pa14 stimulation. In both 
samples, these T cells produced IFN- in response to Pa14-
loaded targets. Unlike normal donors, further rounds of Pa14-
stimulation failed to further expand the Pa14-specific 
population in AML patients and similar results have been 
described by others when examining PRAME-specific T cells 
from leukemia patients (30-32). Using T cells from a patient 
with colon cancer, we were able to demonstrate the successful 
expansion of Pa14-specific T cells from 0.01% of the CD3+ T 
cell population to 0.12% after 3 weeks of stimulation. A further 
expansion to 13.6% of the population after 4 weeks of 
stimulation was achieved, suggesting that the prior exposure or 
the presence of myeloid suppressor cells (33), suppressive factors 
secreted by myeloid leukemia cells (34), and/or inherent defects 
in T cell populations from myeloid leukemia patients (35) may 
be limiting the expansion of T cells from AML patients in our 
assays.
We wished to examine the efficacy of the PASD1 epitopes in a 
clinically applicable vaccine strategy. We chose the p.DOM-
peptide DNA vaccine design due to its ability to provide CD4+ T 
cell help and allow effective CD8+ responses against tumour 
cells, while utilizing a simple and inexpensive production 
system (17). We have previously shown that the CD4+ T helper 
cells expanded by the p.DOM-epitope vaccine are essential for 
effective priming of CD8+ T cells which respond specifically to 
the linked epitope (18-20, 36-38). The p.DOM-epitope vaccine 
has also been shown to induce effective and long-term in vivo
responses against a number of epitopes, including the myeloid 
leukemia-relevant WT1 antigen (36). More recently, the 
p.DOM-epitope vaccine has been used in clinical trials (20), 
allowing the improvement in its delivery for human therapy 
(17). In mice, a relatively large intramuscular volume is believed 
to play a role in the induction of an effective T cell response 
when administering the p.DOM-epitope DNA vaccine. 
However, to achieve something similar in humans, an increased 
transfection rate and inflammation at the injection site would be 
required. Electroporation has been shown to improve responses 
dramatically in mice, particularly at boosting (36) and is now 
being used in clinical trials at our institution with positive long-
term CD8+ responses evident (20).
HHD mice provide a humanized model of HLA-A2 in which 
to examine vaccine efficacy. Using HHD mice, we were able to 
demonstrate that the Pa14 clinically relevant HLA-A*0201-
restricted epitope could induce functional T cells in vivo. We 
demonstrated that the Pa14 modification was essential for an 
effective immune response and that the p.DOM-Pw8 vaccine, in 
the absence of a modified anchor residue, was unable to induce 
T cell responses. To enhance the specificity of the Pa14-induced 
T cells for the endogenously processed Pw8 epitope, we 
expanded CTL lines with Pa14 peptide ex vivo. We showed that 
the CTLs generated could lyse human leukemia cells expressing 
PASD1 from an endogenous source in a HLA-A2-dependent 
manner. CTL killing was reproducible but low, reflecting the www.cancerimmunity.org 5 of 10
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Similarly, heterogenous expression of PASD1 has been 
demonstrated in other cell lines and patient samples (12).
PASD1 has been shown by us and others to be expressed in a 
range of haematological and solid tumour samples (9-13). The 
Pa14 DNA vaccine lends itself to clinical applications in which it 
could be used in conjunction with other vaccines in a range of 
tumour types. MHC class I and II expression on primary AML 
cells provides the necessary signaling pathways for CD8+ CTL 
and CD4+ helper activity, which will be essential for effective 
AML tumour cell lysis induced by any vaccine strategy. 
Immunotherapy is most likely to be applied in first remission 
which can be achieved in most AML patients. It is hoped that 
the activation of T cells when the immune function in patients is 
recovering, following chemotherapy and in first remission, has 
the potential to remove minimal residual disease and delay and 
perhaps even prevent relapse.
The p.DOM-Pa14 DNA vaccine, incorporating a modified 
epitope from the novel CT antigen PASD1, provides a new 
immunotherapeutic treatment for AML, which combines safety 
with cogent immunological advantages. This data continues our 
development and characterization of p.DOM-DNA vaccines 
and provides the first modified CT antigen immunogenic 
peptide for inclusion in a PASD1-targeting vaccine with a 
potential use in clinical trials for solid tumour and leukemia 
patients.
Abbreviations
CT, Cancer/Testis; AML, acute myeloid leukemia; CTL, cyto-
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Materials and methods
Prediction of HLA-A*0201-binding wild-type and modified peptides
Seven nonamers specific for human PASD1 were identified 
using SYFPEITHI (39) and BioInformatics and Molecular 
Analysis Section (BIMAS) (40) algorithms (Table 1). All 
peptides were located in PASD1_v1468-639 and PASD1_v2468-773
(11). Peptide ‘analogues’ of wt peptides 4-10 (Pw4 - Pw10) were 
generated by single amino acid substitutions (at position 2 or 9) 
and denoted Pa11, Pa12, Pa13, Pa14, Pa15, and Pa16. Only those 
wt and analogue peptides with low similarity to known 
eukaryotic proteins were selected for study. The promiscuous 
MHC class II-restricted p30 (41) and the HLA-A2-binding Flu 
M1 (42), CMV pp65 (43) and, in our study, irrelevant WT1.37 
peptides were used where indicated. All peptides were 
synthesized commercially and supplied at > 95% purity (PPR 
Ltd., Southampton, U.K.).
Patient and normal donor samples
Normal donor lymphocytes were obtained from buffy coats 
and CD3+ cells were isolated using Negative Isolation Kits 
(Miltenyi Biotec, Surrey, U.K.) as per manufacturer’s 
instructions. All patient samples were received following 
informed consent and local ethical committee approval in 
accordance with the Declaration of Helsinki. HLA-A2 positivity 
was determined by FACS analysis, followed by subtyping at the 
Anthony Nolan Laboratories, Royal Free Hospital, London. 
Primary AML blasts were obtained from the peripheral blood of 
adult patients with high-count AML at diagnosis and prior to 
the initiation of chemotherapy (Table 2), except for one patient 
who failed to respond to treatment (Patient IV). Peripheral 
blood mononuclear cells (PBMCs) from AML patients were 
purified by Histopaque density gradient centrifugation and 
cryopreserved in X-VIVO 15 (Cambrex Corporation, Berkshire, 
U.K.), 10% DMSO, and 50% human AB serum (both Sigma-
Aldrich, Poole, U.K.). Primary cells were cultured in X-VIVO 15 
medium; AML cells were additionally cultured with 
recombinant human SCF (20 ng/ml) and IL-3 (10 ng/ml) (R&D 
Systems, Minneapolis, U.K.). CD14+ cells were purified from 
remission bone marrow using positive selection MACS CD14 
beads (Miltenyi Biotec). In some cases, CD3+ cells from non-
remission AML or a single colon cancer patient were positively 
isolated using CD3 MACS microbeads (Miltenyi Biotec) as per 
manufacturer’s instructions. Expression of one or both PASD1 
transcripts in AML blasts was determined by PASD1-specific 
RT-PCR using primers targeting the common region of the 
sequence as described previously (9).
Table 2 
Patient characteristics.
Flow cytometry
For the analysis of cell-surface molecules, cells were incubated 
for 20 min at 4°C with directly conjugated antibodies or 
matched isotype controls (all antibodies BD, Oxford, U.K., 
except anti-HLA-A2-FITC from AbD Serotec, Oxford, U.K.) 
and analyzed on a FACSCalibur (BD). Peptide-specific T cells 
were enumerated by pentamer staining. Briefly, 106 cells were 
incubated with 10 μl of peptide-specific or irrelevant control PE-
labeled HLA-A*0201 pentamer (ProImmune, Oxford, U.K.) for 
10 min at room temperature, and washed and co-stained with 
CD8-FITC for 20 min. For detection of intracellular IFN-, 
Brefeldin A (1 mg/ml) was added to stimulated T cells 12 hr 
prior to intracellular staining. Cells were washed with PBS, 
stained with CD8-PE, and then washed twice with HBSS, 1% 
fetal calf serum (FCS). Permeabilization medium (Invitrogen) 
and anti-IFN--FITC were added and incubated for 20 min at 8 of 10 www.cancerimmunity.org
Hardwick et al.room temperature prior to a final wash and analyzed by flow 
cytometry.
Immunolabeling
Cytocentrifuge preparations of cells were fixed in acetone for 
10 min at room temperature, air-dried, wrapped in foil, and 
stored at -20°C. For use, the cytocentrifuge preparations were 
allowed to come up to room temperature before being incubated 
with the monoclonal antibody PASD1-2 (clone 2ALCC128), 
which is specific for aa 540-773 present only in the longer 
PASD1_v2 protein (11). After washing in PBS, the slides were 
stained using the Mach-Three detection kit following 
manufacturer’s instructions. Antigen/antibody complexes were 
visualized using diaminobenzidine tetrahydrochloride substrate 
(Sigma).
Peptide binding assays using T2 cells
The HLA-A2+ T2 cell line (44) was used to assess binding of 
peptides to HLA-A2. T2 cells were incubated overnight in 
complete media (RPMI 1640, 1 mM sodium pyruvate, 2 mM L-
glutamine, 1% non-essential amino acids, 50 μM 2-
mercaptoethanol, 100 U/ml penicillin, 100 μg/ml streptomycin; 
all Invitrogen) with 10% FCS alone or with peptide (0.05-100 
μM) prior to staining with anti-human HLA-A2-FITC antibody 
and FACS analysis. To determine the longevity of binding, 
peptide-pulsed T2 cells were washed three times and replated in 
fresh medium. Aliquots of cells were analyzed at different time 
points after the removal of peptide by flow cytometry.
Generation of DCs
Monocytes were obtained from normal donor buffy coats by 
selection with CD14 MACS beads or by plastic adherence as 
follows: PBMCs were plated at 106/ml in warm X-VIVO 
medium and 1% human AB serum and incubated at 37°C for 4 
hr. Non-adherent cells were removed by gentle washing with 
HBSS and were cryopreserved for later use as effectors. The 
remaining monocytes were cultured in IL-4 (1000 IU/ml) and 
GM-CSF (800 U/ml) for 5 days to induce differentiation to a 
dendritic cell (DC) phenotype. On day 5, a maturation cocktail 
of TNF- (10 ng/ml), IL-6 (1000 U/ml), and IL-1 (10 ng/ml) 
(all R&D Systems) was added. Twenty-four hours later, DCs 
were harvested, washed with HBSS, and used as antigen-
presenting cells (APCs). Confirmation of a DC phenotype was 
determined by flow cytometry.
Stimulation of human T cells
CD3+ or CD8+ cells from normal donors were co-cultured 
with autologous, peptide-pulsed (50 μg/ml, 4 hr) DCs at an 
effector to stimulator ratio of 10:1. IL-7 (10 U/ml) was added to 
the cultures on day 3 and IL-2 (10 U/ml) on day 7. Due to the 
absence of normal monocytes from presentation AML samples, 
T2 cells were used as APCs. T cells were restimulated by the 
addition of irradiated peptide-pulsed APCs on day 7 or day 14, 
together with IL-2 and IL-7 (both 10 U/ml). Supernatants were 
harvested for IFN- detection by ELISA using the Duo set 
ELISA Development System (R&D Systems). Stimulated 
effectors were analyzed for the presence of peptide-specific 
CD8+ T cells by pentamer staining (ProImmune) or IFN-
ELISPOT (BD ELISPOT kit, BD Biosciences, UK). IFN-
ELISPOT assays were carried out using stimulator cells 
(peptide-pulsed T2 at 2x104/well) incubated either alone or with 
effector cells (2x105 per well) in ELISPOT wells pre-coated with 
anti-human IFN- antibody. Plates were incubated for 24 hr at 
37°C, 5% CO2 and spots developed according to manufacturer’s 
instructions (BD Biosciences).
Construction of DNA vaccines
Construction of the p.DOM plasmid containing the first 
domain (DOM) of FrC from tetanus toxin (TT865-1120) with a 
leader sequence derived from the VH of the IgM of the BCL1 
tumour at the N-terminus has been previously described (45). 
DNA vaccines were constructed encoding PASD1691-699 (either 
p.DOM-Pw8 or p.DOM-Pa14) peptides fused directly 3’ to 
DOM. All vaccines were constructed by PCR amplification 
using p.DOM as template with the forward primer:
PCR products were gel purified, digested using HindIII and NotI 
restriction sites, and cloned into the expression vector pcDNA3 
(Invitrogen). Restriction sites within primers are shown in bold 
and PASD1-peptide encoding sequences are italicized. The 
modified sequence is underlined. Integrity of the inserted 
sequences were confirmed by DNA sequencing and translated 
product size was checked in vitro using the TNT T7 coupled 
reticulocyte lysate system (Promega, Southampton, U.K.).
Vaccination of HHD transgenic mice
Permission to use the HHD mice was kindly provided by Dr. 
François Lemonnier, Departement d’Immunologie, Institut 
Pasteur, France. HHD mice express a hybrid human HLA-A2 
transgene, comprising the human 1 and 2 domains, fused to 
the murine H-2Db 3 transmembrane and intracytoplasmic 
domain, and covalently linked to human -2 microglobulin. 
HHD mice lack mouse MHC class I molecules due to targeted 
disruption of the H-2Db and mouse 2-microglobulin genes 
(46). HHD mice at 6 to 10 weeks of age were injected 
intramuscularly (i.m.) into both quadriceps with a total of 50 μg 
DNA in saline solution on day 0. Where indicated, mice were 
boosted with the same DNA vaccine delivered with in vivo
electroporation on day 28 as described previously (47). Animal 
experimentation was conducted within local Ethical Committee 
and UK Coordinating Committee for Cancer Research 
(London, U.K.) guidelines under Home Office License.
Mouse IFN--ELISPOT
Vaccine-specific IFN- secretion by splenocytes from 
individual mice was assessed directly ex vivo (BD ELISPOT Set, 
BD) on day 14 or 36, as described previously (18). Splenocytes 
were incubated in triplicate, alone, with Pw8 or Pa14 peptides, 
or with irrelevant peptide to assess CD8+ T cell responses, or 
with p30 peptide to assess CD4+ T cell responses. Data are 
expressed as the frequency of spot-forming cells (SFCs) per 
million lymphocytes. For analysis of peptide-specific T cell 
sensitivity, cells were incubated with a range of peptide 
concentrations; the number of SFC/million cells at the peptide 
concentration inducing the greatest response was assigned a 
value of 100%. For each peptide concentration tested, the 
percent maximal response was then calculated by the formula: 
(experimental SFCs per million cells / maximal SFCs per million 
cells) x 100% for each individual animal.www.cancerimmunity.org 9 of 10
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For the generation and maintenance of CTL lines, splenocytes 
from individual mice were resuspended in 10-15 ml complete 
medium with Pw8 or Pa14 (1 μM) peptides. For further cycles of 
in vitro restimulation, cells were washed and resuspended at 
3x105/mL with 2.5x106/mL syngeneic splenocytes (pre-
incubated for 1 hr with the relevant peptide at 1 μM, washed 4 
times in unsupplemented RPMI 1640, and irradiated at 2,500 
rad). Recombinant human IL-2 was added to cultures at 20 IU/
mL (Perkin-Elmer, Foster City, CA) and cells were incubated at 
2 mL/well in a 24-well plate. Subsequent cycles of in vitro
restimulation were carried out similarly every 7-10 days. Lytic 
activity was assessed by standard 5 hr 51Cr release assay as 
previously described (48). Cells used as targets in CTL assays 
were the human leukemia line K562 (HLA-A*0201-, PASD1+) 
and the human colon cancer cell line SW480 (HLA-A*0201+, 
PASD1+). K562 were transduced with the MSCV retroviral 
vector alone to produce K562-RV or with the MSCV retroviral 
vector containing HHD cDNA to produce K562-HHD cell lines. 
PASD1 protein expression was determined using the PASD1-2 
antibody as described previously (12). For some experiments, 
target cells were incubated with the anti-human HLA-class I 
monoclonal antibody W6.32 (Diaclone, Besancon, France) at 5 
μg/well for 15 min at 4°C before the addition of T cells and for 
the duration of the assay. Means of triplicate cultures were 
expressed as (experimental release – spontaneous release) / 
(total 51Cr incorporated – spontaneous release) x 100%. The 
average spontaneous release never exceeded 15% of the total 
incorporated 51Cr.
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